During the diagnosis of breast cancer, breast cancer is divided into four types based on the presence of estrogen receptors, progesterone receptors and HER-2 receptors on the surface of the tumor cells. Triple negative breast cancer is a type of breast cancer that is negative for estrogen receptor, progesterone receptor and HER-2 receptor. For patients with this type of breast cancer, endocrine therapy and traditional targeted HER-2 drugs cannot be used. Therefore, many patients with triple-negative breast cancer believe that chemotherapy is the only treatment option for this type of disease. But in fact, targeted therapy for triple negative breast cancer has been on the path of exploration. For targeted therapy of triple negative breast cancer, there are several pathways that can be explored: 1. The epidermal growth factor receptor pathway. The drugs in this area are gefitinib, erlotinib and cetuximab. Among triple-negative breast cancers, the expression rate of epidermal growth factor receptor is high, and there are also clinical trials with better data; 2. Anti-angiogenic drugs, such as bevacizumab, which targets the vascular endothelial growth factor receptor. PARP inhibitors work on the pathway of homologous recombination repair, and the representative drug is olaparib. There are also clinical trial data to support its application; 4. Because most triple negative breast cancers have androgen receptor expression, androgen receptor antagonists can also be used to treat triple negative breast cancers. For targeted therapy of triple negative breast cancer, although there are many pathways that can be explored, there is no convincing phase III clinical trial data to support it so far, so targeted therapy of triple negative breast cancer is still on the way of exploration.